AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25199696 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (2 mL)
Number of subjects: 268
Study 23665915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 1.0 mg/kg
Number of subjects: 80
Study 23665915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0 mg/kg
Number of subjects: 80
Study 23665915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 0.5 mg/kg
Number of subjects: 80
Study 23665915 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine 0.05 mg/kg
Number of subjects: 80
Study 19912273 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant placement into extraction sockets
Number of subjects: 93
Study 18331601 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP (doxorubicin 50 mg/m2)
Number of subjects: 0
Study 18331601 — intervention group
Group type: COMPARATOR
Intervention: CNOP (mitoxantrone 10-12 mg/m2)
Number of subjects: 0
Study 16027794 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a plus ribavirin
Number of subjects: 54
Study 14634144 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estriol treatment
Number of subjects: 0
Study 10680109 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ketamine (0.2 mg/kg)
Number of subjects: 48
Study 10680109 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural neostigmine (100 micrograms)
Number of subjects: 48
Study 10680109 — intervention group
Group type: COMPARATOR
Intervention: Epidural midazolam (500 micrograms)
Number of subjects: 48
Study 10680109 — intervention group
Group type: COMPARATOR
Intervention: Control group (2 mg epidural morphine)
Number of subjects: 48
Study 8735759 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 91
Study 8735759 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 91
Study 1768504 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% dextrose water (D)
Number of subjects: 24
Study 1768504 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% mannitol (M)
Number of subjects: 24
Study 1768504 — intervention group
Group type: EXPERIMENTAL
Intervention: 23.5% saline (S)
Number of subjects: 24
Study 1768504 — intervention group
Group type: COMPARATOR
Intervention: All three agents (D, M, S)
Number of subjects: 24
Study 6450001 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of beta-thromboglobulin
Number of subjects: 19
Study 6450001 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of platelet factor 4
Number of subjects: 19
Study 6450001 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of thromboxane B2
Number of subjects: 19
Study 6450001 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of fibrinopeptide A
Number of subjects: 19
Study 31845587 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate with 24 weeks of atypical antipsychotic
Number of subjects: 159
Study 31845587 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium with 24 weeks of atypical antipsychotic
Number of subjects: 159
Study 31845587 — intervention group
Group type: COMPARATOR
Intervention: Valproate
Number of subjects: 159
Study 31845587 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 159
Study 31499383 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg/m2/d for 14 days
Number of subjects: 174
Study 31499383 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 6 mg/m2/d for 28 days (standard dosing)
Number of subjects: 174
Study 28630378 — intervention group
Group type: EXPERIMENTAL
Intervention: blue-enriched white light (17,000 K, 89 lux; n=36)
Number of subjects: 71
Study 28630378 — intervention group
Group type: COMPARATOR
Intervention: standard white light (4000 K, 84 lux; n=35)
Number of subjects: 71
Study 27063678 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer support for self-managed computerised aphasia treatment
Number of subjects: 0
Study 27063678 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and ongoing structured support from a trained speech-language pathologist
Number of subjects: 0
Study 23843178 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual pattern group
Number of subjects: 0
Study 23843178 — intervention group
Group type: COMPARATOR
Intervention: Visual random group
Number of subjects: 0
Study 22360874 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 2198
Study 22360874 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory improvement intervention
Number of subjects: 2198
Study 19509381 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-practice CCTA scan model (minimized scan range, heart rate reduction, electrocardiographic-gated tube current modulation, reduced tube voltage)
Number of subjects: 4995
Study 19509381 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-practice CCTA scan model
Number of subjects: 4995
Study 19509381 — intervention group
Group type: COMPARATOR
Intervention: Control period (July-August 2007)
Number of subjects: 4995
Study 17906429 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocrystalline silver dressings under 4-layer compression bandages
Number of subjects: 15
Study 15361493 — intervention group
Group type: COMPARATOR
Intervention: Nutrient challenge
Number of subjects: 482
Study 15361493 — intervention group
Group type: COMPARATOR
Intervention: Gastric emptying time (GET)
Number of subjects: 482
Study 11224838 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic medicine
Number of subjects: 75
Study 11224838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 9588664 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg orally)
Number of subjects: 12
Study 9588664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8026027 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin 80 mg/d
Number of subjects: 270
Study 8026027 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 270
Study 2574905 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine
Number of subjects: 8
Study 2574905 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine
Number of subjects: 8
Study 2574905 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentasa
Number of subjects: 8
Study 2574905 — intervention group
Group type: EXPERIMENTAL
Intervention: Salofalk
Number of subjects: 8
Study 2574905 — intervention group
Group type: EXPERIMENTAL
Intervention: Asacol
Number of subjects: 8
Study 53555 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg orally
Number of subjects: 5
Study 30389897 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent Retriever (SR) with >3 passes
Number of subjects: 281
Study 30389897 — intervention group
Group type: COMPARATOR
Intervention: Stent Retriever (SR) with ≤3 passes
Number of subjects: 281
Study 30389897 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact Aspiration (CA) with >3 passes
Number of subjects: 281
Study 30389897 — intervention group
Group type: COMPARATOR
Intervention: Contact Aspiration (CA) with ≤3 passes
Number of subjects: 281
Study 28841537 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 10
Study 28841537 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Stretching (DS)
Number of subjects: 10
Study 28841537 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 10
Study 25568167 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed cytology for HPV-positive women
Number of subjects: 0
Study 23452864 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based hygiene intervention led by Community Motivators promoting hand-washing with soap
Number of subjects: 88
Study 23452864 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 88
Study 21190985 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg twice daily lorcaserin
Number of subjects: 57
Study 21190985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 18342968 — intervention group
Group type: EXPERIMENTAL
Intervention: Doranidazole
Number of subjects: 0
Study 18342968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15730351 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine 20 mg
Number of subjects: 67
Study 15730351 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg
Number of subjects: 67
Study 15730351 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg
Number of subjects: 67
Study 15730351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 14514943 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute PVW (n=84)
Number of subjects: 84
Study 14514943 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescence (n=20)
Number of subjects: 84
Study 14514943 — intervention group
Group type: COMPARATOR
Intervention: Current wheeze (n=18)
Number of subjects: 84
Study 14514943 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (n=15)
Number of subjects: 84
Study 10663002 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 60
Study 10663002 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (AA)
Number of subjects: 60
Study 8867534 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1618109 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil (400 mg/m2 daily for 5 days)
Number of subjects: 139
Study 1618109 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil combined with folic acid (100 mg/m2 before each dose of fluorouracil)
Number of subjects: 139
Study 6324332 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine tablets, 150 mg twice daily
Number of subjects: 48
Study 6324332 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 48
Study 31187447 — intervention group
Group type: EXPERIMENTAL
Intervention: Bergamot oil nanospanlastics combined with PUVB therapy
Number of subjects: 0
Study 31187447 — intervention group
Group type: EXPERIMENTAL
Intervention: Bergamot oil nanospanlastics
Number of subjects: 0
Study 31187447 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanlastics
Number of subjects: 0
Study 30672225 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 30672225 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 0
Study 26547718 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised version of the FDA Drug Safety Communication (DSC)
Number of subjects: 1244
Study 26547718 — intervention group
Group type: COMPARATOR
Intervention: Standard version of the FDA Drug Safety Communication (DSC)
Number of subjects: 1244
Study 26547718 — intervention group
Group type: EXPERIMENTAL
Intervention: Both versions of the FDA Drug Safety Communication (DSC)
Number of subjects: 1244
Study 24740826 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin/cyclophosphamide (EC, 90/600 mg/m2 q3w) followed by docetaxel (D, 100 mg/m2 q3w) with bevacizumab (B, 15 mg/kg q3w)
Number of subjects: 1948
Study 24740826 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin/cyclophosphamide (EC, 90/600 mg/m2 q3w) followed by docetaxel (D, 100 mg/m2 q3w) without bevacizumab
Number of subjects: 1948
Study 22038481 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care intervention (details not specified)
Number of subjects: 108
Study 20404353 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vigabatrin (100-148 mg/kg/d)
Number of subjects: 221
Study 20404353 — intervention group
Group type: COMPARATOR
Intervention: Low-dose vigabatrin (18-36 mg/kg/d)
Number of subjects: 221
Study 20404353 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up cohort
Number of subjects: 221
Study 28933338 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 µg of lubiprostone 30 minutes prior to the study
Number of subjects: 80
Study 28933338 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 µg of lubiprostone plus 10 mg of domperidone 30 minutes prior to the study
Number of subjects: 80
Study 28933338 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 80
Study 12603500 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/day for 12 months
Number of subjects: 23
Study 12603500 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific treatment mentioned)
Number of subjects: 23
Study 12603500 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 23
Study 12603500 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study 12603500 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan and Control group
Number of subjects: 23
Study 11061253 — intervention group
Group type: COMPARATOR
Intervention: Riluzole 100 mg/day
Number of subjects: 43
Study 11061253 — intervention group
Group type: COMPARATOR
Intervention: Riluzole 200 mg/day
Number of subjects: 43
Study 11061253 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 43
Study 9359740 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated Japanese encephalitis vaccine (SA14-14-2)
Number of subjects: 26239
Study 9359740 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccine)
Number of subjects: 26239
Study 8228195 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced condition
Number of subjects: 40
Study 8228195 — intervention group
Group type: COMPARATOR
Intervention: Externally paced condition
Number of subjects: 40
Study 2419635 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular hydroxyethyl starch
Number of subjects: 0
Study 2419635 — intervention group
Group type: COMPARATOR
Intervention: Low molecular dextran
Number of subjects: 0
Study 29597007 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 950
Study 29597007 — intervention group
Group type: COMPARATOR
Intervention: Febuxostat
Number of subjects: 950
Study 26617202 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (40-60 mg twice daily for 28 consecutive days, followed by a 14-day break)
Number of subjects: 618
Study 26617202 — intervention group
Group type: COMPARATOR
Intervention: Taxane (docetaxel 60-75 mg/m2 at intervals of 3-4 weeks; paclitaxel 80-100 mg/m2 weekly for 3 of 4 weeks; or paclitaxel 175 mg/m2 at intervals of 3-4 weeks)
Number of subjects: 618
Study 26617202 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 618
Study 26617202 — intervention group
Group type: COMPARATOR
Intervention: Taxane
Number of subjects: 618
Study 25465683 — intervention group
Group type: EXPERIMENTAL
Intervention: Transepithelial corneal collagen crosslinking (CXL)
Number of subjects: 25
Study 22898443 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine loading protocol
Number of subjects: 47
Study 22898443 — intervention group
Group type: COMPARATOR
Intervention: Symptom-triggered treatment protocol
Number of subjects: 47
Study 19664302 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (260 mg DHA + 60 mg EPA per g) at doses of 2 g/d
Number of subjects: 67
Study 19664302 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (260 mg DHA + 60 mg EPA per g) at doses of 4 g/d
Number of subjects: 67
Study 19664302 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (260 mg DHA + 60 mg EPA per g) at doses of 6 g/d
Number of subjects: 67
Study 19664302 — intervention group
Group type: COMPARATOR
Intervention: Sunola oil (control; 6 g/d)
Number of subjects: 67
Study 18678802 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (n = 33)
Number of subjects: 65
Study 18678802 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 32)
Number of subjects: 65
Study 15358441 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oral estradiol (E(2)) continuously during two 28‐day cycles
Number of subjects: 26
Study 15358441 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oral estradiol (E(2)) continuously during two 28‐day cycles + 800 mg of vaginal progesterone
Number of subjects: 26
Study 15358441 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pregnanolone (3alpha‐hydroxy‐5beta‐pregnan‐20‐one)
Number of subjects: 26
Study 15358441 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2) alone or E(2)+progesterone
Number of subjects: 26
Study 12618680 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective stent placement
Number of subjects: 227
Study 12618680 — intervention group
Group type: COMPARATOR
Intervention: Systematic stent placement
Number of subjects: 227
Study 12618680 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty and stent (Selective)
Number of subjects: 227
Study 10227648 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray
Number of subjects: 14
Study 10227648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8914872 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonthoracotomy
Number of subjects: 193
Study 8914872 — intervention group
Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 193
Study 8914872 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonthoracotomy (in patients with left ventricular ejection fraction <30%)
Number of subjects: 193
Study 8914872 — intervention group
Group type: COMPARATOR
Intervention: Thoracotomy (in patients with left ventricular ejection fraction <30%)
Number of subjects: 193
Study 1725537 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting diltiazem
Number of subjects: 60
Study 1725537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 6316307 — intervention group
Group type: EXPERIMENTAL
Intervention: High fibre, low fat and low sodium dietary regime
Number of subjects: 53
Study 6316307 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 53
Study 31996395 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT+anti-CTLA4
Number of subjects: 33
Study 31996395 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT+anti-PD1
Number of subjects: 33
Study 30059995 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF assay
Number of subjects: 1842
Study 30059995 — intervention group
Group type: COMPARATOR
Intervention: LED-FM
Number of subjects: 1842
Study 30059995 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF assay (subgroup analysis)
Number of subjects: 1842
Study 28072459 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing integrated with cognitive behavioral therapy (MI-CBT)
Number of subjects: 8
Study 28072459 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT) alone
Number of subjects: 8
Study 26651463 — intervention group
Group type: EXPERIMENTAL
Intervention: Just-in-time adaptive interventions (JITAIs)
Number of subjects: 0
Study 26651463 — intervention group
Group type: EXPERIMENTAL
Intervention: Microrandomized trials
Number of subjects: 0
Study 24366622 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma total homocysteine concentration
Number of subjects: 258
Study 24366622 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density
Number of subjects: 258
Study 24366622 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma homocysteine increase of 5.0 μmol/l
Number of subjects: 258
Study 24366622 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma homocysteine level
Number of subjects: 258
Study 23167181 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus antifungal therapy during operation and postoperation
Number of subjects: 102
Study 23167181 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 102
Study 19419318 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAX with FN BMD
Number of subjects: 3221
Study 19419318 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAX without FN BMD
Number of subjects: 3221
Study 19419318 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalent vertebral fracture plus age and FN BMD
Number of subjects: 3221
Study 19419318 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of prevalent vertebral fracture and FRAX with FN BMD
Number of subjects: 3221
Study 19419318 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline vertebral fracture status plus age and FN BMD
Number of subjects: 3221
Study 19419318 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAX for major osteoporotic fractures (with and without FN BMD)
Number of subjects: 3221
Study 17717245 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg
Number of subjects: 100
Study 17717245 — intervention group
Group type: COMPARATOR
Intervention: IV normal saline (Control)
Number of subjects: 100
Study 15597657 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral approach
Number of subjects: 42
Study 15597657 — intervention group
Group type: COMPARATOR
Intervention: Posterior approach
Number of subjects: 42
Study 11276268 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 arm supports
Number of subjects: 21
Study 11276268 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 arm support
Number of subjects: 21
Study 11276268 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 21
Study 9412659 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (n = 5)
Number of subjects: 11
Study 9412659 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine (n = 6)
Number of subjects: 11
Study 8505824 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative total parenteral nutrition (TPN)
Number of subjects: 0
Study 3325316 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg fentiazac twice daily for 3 weeks
Number of subjects: 19
Study 3325316 — intervention group
Group type: COMPARATOR
Intervention: 50 mg diclofenac sodium twice daily for 3 weeks
Number of subjects: 19
Study 29642492 — intervention group
Group type: EXPERIMENTAL
Intervention: Trp-3.0g
Number of subjects: 32
Study 29642492 — intervention group
Group type: EXPERIMENTAL
Intervention: Trp-1.5g
Number of subjects: 32
Study 29642492 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 27193744 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidifier (HH)
Number of subjects: 40
Study 27193744 — intervention group
Group type: COMPARATOR
Intervention: Non-heated humidifier (non-HH)
Number of subjects: 40
Study 25749595 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chih (TCC)
Number of subjects: 90